This report was first published by Endpoints News. To see the original version, click here
Here we go again?
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline at all doses after 18 months, based on pre-planned analyses from the trial.
您已阅读7%（359字），剩余93%（4677字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。